ArticleFrontiers in immunology2013
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03044743 (A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.Archivum immunologiae et therapiae experimentalis · 2023Review
- Challenges of Anti-Mesothelin CAR-T-Cell Therapy.Cancers · 2023Review
- Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.Molecular cancer · 2022Review
- Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells.Iranian journal of basic medical sciences · 2021Article
- Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.Journal for immunotherapy of cancer · 2020Article
- CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics.Cancer cell international · 2019Review
- Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated ImmunosuppressionFrontiers in immunology · 2019Article
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.Frontiers in pharmacology · 2018Article
- Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases.Frontiers in cell and developmental biology · 2018Review
- Extracellular ISG15 Signals Cytokine Secretion through the LFA-1 Integrin Receptor.Molecular cell · 2017Article
- Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.Protein & cell · 2017Review
- Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Cancer gene therapy · 2017Review
- Cornerstones of CRISPR-Cas in drug discovery and therapy.Nature reviews. Drug discovery · 2017Review
- Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.Immunology and cell biology · 2016Article
- Targeting CD73 in the tumor microenvironment with MEDI9447.Oncoimmunology · 2016Article
- SHP-1: the next checkpoint target for cancer immunotherapy?Biochemical Society transactions · 2016Review
- RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?International journal of molecular sciences · 2016Review
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.Scientific reports · 2016Article
- Synthetic biology in cell-based cancer immunotherapy.Trends in biotechnology · 2015Review
- Bench, bedside, toolbox: T-cells deliver on every level.Frontiers in immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent early stage clinical trials evaluating the adoptive transfer of patient CD8(+) T-cells re-directed with antigen receptors recognizing tumors have shown very encouraging results. These reports provide strong support for further development of the therapeutic concept as a curative cancer treatment. In this respect combining the adoptive transfer of tumor-specific T-cells with therapies that increase their anti-tumor capacity is viewed as a promising strategy to improve treatment outcome. The ex vivo genetic engineering step that underlies T-cell re-direction offers a unique angle to combine antigen receptor delivery with the targeting of cell-intrinsic pathways that restrict T-cell effector functions. Recent progress in genome editing technologies such as protein- and RNA-guided endonucleases raise the possibility of disrupting gene expression in T-cells in order to enhance effector functions or to bypass tumor immune suppression. This approach would avoid the systemic administration of compounds that disrupt immune homeostasis, potentially avoiding autoimmune adverse effects, and could improve the efficacy of T-cell based adoptive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.